Biotechnology

Bio-Path

Bio-Path released FY2025 Q2 earnings on August 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.5533 (forecast USD -0.4)

Bio-Path released FY2025 Semi-Annual earnings on August 14, 2025 (EST) with actual revenue of USD 0 and EPS of USD -0.9689

Bio-Path CEO to speak at Life Science Investor Forum

Stonegate Updates Coverage on Bio-Path: Clinical Trial Progress of Candidate Drugs

Bio-Path Holdings Provides Clinical and Operational Updates

Bio-Path released FY2025 Q1 earnings on May 15 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.4038 (forecast USD -0.38)

Bio-Path Holdings Receives Quick Capital Promissory Note Financing

Bio-Path released FY2024 Q4 earnings on March 27 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -0.638 USD (forecast -0.37 USD)

Bio-Path released FY2024 annual earnings on March 27 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -4.1207 USD (forecast -3.17 USD)

Tumor Shrinkage in BP1001-A Clinical Trial Patient

Bio-Path Holdings Updates Clinical Trial of BP1002 for Refractory Acute Myeloid Leukemia

Bio-Path released FY2024 9 Months Earnings on November 14 After-Market EST with actual revenue of USD 0 and EPS of USD -6.7398

Bio-Path released FY2024 Q3 earnings on November 14 After-Market (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -0.701 USD (forecast -1.02 USD)

Bio-Path to Release FY2024 Q3 Earnings on November 15 After-Market EST, Forecasted Revenue 0 USD, EPS -1.02 USD

Bio-Path Holdings, Inc. Announces Development of Targeted Nucleic Acid Cancer Drugs

Bio-Path Holdings (BPTH) Announces Positive Progress in BP1001-A Solid Tumor Study

Bio-Path's net income for the second quarter is -$1.9 million

Bio-Path Holdings announces clinical progress and outlines expansion strategy

Bio-Path Holdings reaches private placement agreement

Bio-Path released FY2024 Q1 earnings on May 14 After-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -4.8794 (forecast USD -4.54)

Mega Fortune

Processa Pharmaceuticals

cbdMD

Agape ATP

VYNE Therapeutics

Andersen

Inspirato

Medline Inc.

Creative Global Tech

GCI LIBERTY INC COM USD0.01 SER C SUBS RTS 17/12/2025

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap